|
|
|
(For ADPKD)
Tolvaptan |
Otsuka Maryland Research Institute
This study, which recently received “fast track” designation by
the Food and Drug Administration because of its promise as a
treatment for PKD, is looking at the effectiveness of a
vasopressin antagonist drug to slow or stop cyst growth in ADPKD
patients. Phase II clinical trials are finishing up. Enrollment
has not yet begun for Phase III clinical trials. Phase III trials
are larger studies looking at drug effectiveness in ADPKD patients
living in the Americas, Asia, and Europe. Contact Otsuka at
866-712-5837 for more information.
Rapamycin (Slrolimus/Rapamune)
This study is a Phase I/Phase II prospective, randomized,
placebo-controlled clinical trial sponsored bye the Cleveland
Clinic and designed to evaluate the effects of an agent (Rapamycin)
that has antiproliferative, antiangiogenesis and tumor-progression
blocking capabilities. This study is not yet open for patient
recruitment. For more information, type in “polycystic kidney
disease” and select “Pilot Study of Rapamycin as Treatment for
Autosomal Dominant PKD.”
Somatostatin
This general aim of this study is to compare the effects on
disease progression of three year treatment regimen using
long-acting Somatostatin or placebo in patients with ADPKD and
normal renal function or mild to moderate renal insufficiency.
This is a Phase III study sponsored by the Mario Negri Institute
for Pharmacological Research in Bergamo, Italy. This study is not
yet open for patient recruitment. For more information, go to
www.clinicaltrials.gov/ct/ and type in “polycystic kidney
disease”. Then select “Somatostatin in Polycystic Kidney: A
Long-Term Three Year Follow-up Study.”
|
